MARKET

TECX

TECX

Tectonic Therapeutic Inc
NASDAQ
29.00
+2.13
+7.93%
After Hours: 29.50 +0.5 +1.72% 19:50 05/08 EDT
OPEN
27.00
PREV CLOSE
26.87
HIGH
30.36
LOW
27.00
VOLUME
432.69K
TURNOVER
--
52 WEEK HIGH
36.03
52 WEEK LOW
14.39
MARKET CAP
546.61M
P/E (TTM)
-7.1658
1D
5D
1M
3M
1Y
5Y
1D
LifeSci Capital Remains a Buy on Tectonic Therapeutic (TECX)
TipRanks · 16h ago
Piper Sandler Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)
TipRanks · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tectonic Therapeutic (TECX), Cullinan Management (CGEM) and Siemens Healthineers AG (OtherSEMHF)
TipRanks · 2d ago
Analyst Reaffirms Buy on Tectonic Therapeutic, Lifts Price Target to $88 on TX-45 Clinical Momentum and Expanded Market Opportunity
TipRanks · 2d ago
Tyler Van Buren Reiterates Buy on Tectonic as Advancing TX45 Program, Expanded Pipeline, and Strong Cash Runway Support Favorable Long-Term Risk‑Reward
TipRanks · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
TipRanks · 2d ago
Tectonic Therapeutic GAAP EPS of -$1.34 misses by $0.17
Seeking Alpha · 2d ago
Tectonic Therapeutic Q1 EPS $(1.34) Misses $(1.18) Estimate
Benzinga · 2d ago
More
About TECX
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.

Webull offers Tectonic Therapeutic Inc stock information, including NASDAQ: TECX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TECX stock methods without spending real money on the virtual paper trading platform.